JPH1099087A - インターロイキン−１ベータ転換酵素様アポプロシス性プロテアーゼ−６ - Google Patents

インターロイキン−１ベータ転換酵素様アポプロシス性プロテアーゼ−６

Info

Publication number
JPH1099087A
JPH1099087A JP9167838A JP16783897A JPH1099087A JP H1099087 A JPH1099087 A JP H1099087A JP 9167838 A JP9167838 A JP 9167838A JP 16783897 A JP16783897 A JP 16783897A JP H1099087 A JPH1099087 A JP H1099087A
Authority
JP
Japan
Prior art keywords
polypeptide
polynucleotide
ice
dna
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP9167838A
Other languages
English (en)
Japanese (ja)
Other versions
JPH1099087A5 (https=
Inventor
Vishva M Dixit
ビシュバ・エム・ディキシット
Wei-Wu He
ウェイ−ウー・ヘ
Kristine K Kikly
クリスティン・ケイ・キクリー
M Ruben Steven
スティーブン・エム・ルーベン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
SmithKline Beecham Corp
University of Michigan Ann Arbor
Original Assignee
Human Genome Sciences Inc
SmithKline Beecham Corp
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, SmithKline Beecham Corp, University of Michigan Ann Arbor filed Critical Human Genome Sciences Inc
Publication of JPH1099087A publication Critical patent/JPH1099087A/ja
Publication of JPH1099087A5 publication Critical patent/JPH1099087A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP9167838A 1996-05-20 1997-05-20 インターロイキン−１ベータ転換酵素様アポプロシス性プロテアーゼ−６ Withdrawn JPH1099087A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1794996P 1996-05-20 1996-05-20
US2034496P 1996-05-23 1996-05-23
US1896196P 1996-06-05 1996-06-05
US60/018961 1996-06-05
US60/017949 1996-06-05
US60/020344 1996-06-05

Publications (2)

Publication Number Publication Date
JPH1099087A true JPH1099087A (ja) 1998-04-21
JPH1099087A5 JPH1099087A5 (https=) 2005-04-07

Family

ID=27360935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9167838A Withdrawn JPH1099087A (ja) 1996-05-20 1997-05-20 インターロイキン−１ベータ転換酵素様アポプロシス性プロテアーゼ−６

Country Status (2)

Country Link
US (3) US6010878A (https=)
JP (1) JPH1099087A (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010878A (en) * 1996-05-20 2000-01-04 Smithkline Beecham Corporation Interleukin-1 β converting enzyme like apoptotic protease-6
US6455296B2 (en) * 1997-05-29 2002-09-24 Thomas Jefferson University Apoptotic protease Mch6, nucleic acids encoding same and methods of use
EP1932914A3 (en) * 1998-06-02 2008-09-03 Vertex Pharmceuticals Incorporated Caspase-9 deficient animals and the use thereof
US20030078211A1 (en) * 1998-06-24 2003-04-24 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6492170B1 (en) * 2000-09-11 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 9 expression
EP1283052A1 (en) * 2001-08-10 2003-02-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Pharmaceutical composition containing caspase-8 and /or caspase-9 useful for overcoming glucocorticoid- and cancer therapy-induced apoptosis of tumours
US7332158B2 (en) * 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
US7048922B2 (en) * 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
US20060057121A1 (en) * 2004-09-10 2006-03-16 Demao Yang Compositions and treatments using ex vivo activated cells for myelosuppressed patients
CN102859003B (zh) 2010-03-08 2014-07-30 达纳-法伯癌症研究院有限公司 使用参考封闭序列的全cold-pcr富集
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
EP3333269B1 (en) 2011-03-31 2021-05-05 Dana-Farber Cancer Institute, Inc. Methods to enable multiplex cold-pcr
US9434935B2 (en) * 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2912172A1 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
ES2904301T3 (es) 2014-11-03 2022-04-04 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Receptores de células T dirigidos contra Bob1 y usos de los mismos
US11371090B2 (en) 2016-12-12 2022-06-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for molecular barcoding of DNA molecules prior to mutation enrichment and/or mutation detection
WO2019023243A1 (en) 2017-07-24 2019-01-31 Dana-Farber Cancer Institute, Inc. METHODS AND COMPOSITIONS FOR SELECTING AND AMPLIFYING DNA TARGETS IN A SINGLE REACTION MIXTURE
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000353A1 (en) * 1991-06-20 1993-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US6010878A (en) * 1996-05-20 2000-01-04 Smithkline Beecham Corporation Interleukin-1 β converting enzyme like apoptotic protease-6

Also Published As

Publication number Publication date
US20050089984A1 (en) 2005-04-28
US6010878A (en) 2000-01-04
US7115260B2 (en) 2006-10-03
US6294169B1 (en) 2001-09-25

Similar Documents

Publication Publication Date Title
JPH1099087A (ja) インターロイキン−１ベータ転換酵素様アポプロシス性プロテアーゼ−６
AU2002213138B2 (en) Novel serine protease genes related to DPPIV
US20020119554A1 (en) Arginase II
US6008042A (en) Interleukin-1 beta converting enzyme like apoptotic protease-7
US5861298A (en) Cathepsin K gene
US6107473A (en) Kringle-related clone HTHBZ47
US5948669A (en) Rat cathepsin K polynucleotide and polypeptide sequence
WO1997047643A1 (en) Cathepsin k gene
US6274717B1 (en) Splicing variant of human membrane-type matrix metalloproteinease-5 (MT-MMP5-L)
EP0841399A2 (en) Mammalian fin-1 nucleic acid (a caspase) and protein sequences and uses therefor
US6890721B1 (en) Interleukin-1β converting enzyme like apoptotic protease-6
EP0808904A2 (en) Interleukin-1 beta converting enzyme like apoptotic protease-6
EP0812916A2 (en) Cathepsin k gene
EP0887416A2 (en) Human AFC1
JPH10117788A (ja) ヒト・ｍｙｔ−１キナーゼクローン
US20040171059A1 (en) Interleukin-1 beta converting enzyme like apoptosis protease-3 and -4
JPH10146195A (ja) 良性前立腺肥大と関連するポリヌクレオチドおよびポリペプチド
WO1997046662A1 (en) Interleukin-1 beta converting enzyme like apoptotic protease-7
JP2002186492A (ja) ヒトｒｃｅ１
US6207803B1 (en) Human requiem
US6121018A (en) Interleukin-1β converting enzyme like apoptosis protease-10
AU2006228068B2 (en) Novel serine protease genes related to DPPIV
JPH10201489A (ja) ｈＲＡＤ５４

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040512

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060314